In the latest trading session,, 0.48 million Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares changed hands as the company’s beta touched 1.00. With the company’s most recent per share price at $9.90 changed hands at -$0.09 or -0.90% at last look, the market valuation stands at $1.36B. ARWR’s current price is a discount, trading about -207.17% off its 52-week high of $30.41. The share price had its 52-week low at $9.57, which suggests the last value was 3.33% up since then. When we look at Arrowhead Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.08 million shares, with the 3-month average coming to 2.00 million.
Analysts gave the Arrowhead Pharmaceuticals Inc (ARWR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended ARWR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Arrowhead Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.46.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Instantly ARWR was in red as seen in intraday trades today. With action -21.99%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -47.34%, with the 5-day performance at -21.99% in the red. However, in the 30-day time frame, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is -34.26% down. Looking at the short shares, we see there were 10.44 million shares sold at short interest cover period of 7.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is 26.98, meaning bulls need an upside of 63.31% from its recent market value. According to analyst projections, ARWR’s forecast low is 24 with 29.97 as the target high. To hit the forecast high, the stock’s price needs a -202.73% plunge from its current level, while the stock would need to soar -142.42% for it to hit the projected low.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
Year-over-year growth is forecast to reach 8,932.46% up from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 116.27M. 11 analysts are of the opinion that Arrowhead Pharmaceuticals Inc’s revenue for the current quarter will be 51.27M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Arrowhead Pharmaceuticals Inc earnings to increase by 47.20%, but the outlook for the next 5-year period is at 11.30% per year.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.19% of Arrowhead Pharmaceuticals Inc shares while 74.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 86.01%. There are 74.66% institutions holding the Arrowhead Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 12.6275% of the shares, roughly 15.68 million ARWR shares worth $407.61 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.9072% or 12.21 million shares worth $317.44 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 7.92 shares estimated at $77.57 million under it, the former controlled 5.77% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.67% of the shares, roughly 3.66 shares worth around $35.86 million.
